Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; none of the 26 sources its claims cite is checked for support yet.

Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder

Open access

Abstract

Aims: To evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis. Methods: Adults with a BP-I diagnosis (first claim = index), commercial, Medicare Supplemental, or Medicaid insurance, and ≥1 outpatient cariprazine dispensing were identified from Merative MarketScan database. Cohorts included patients who initiated cariprazine as either their first or subsequent AA after initial BP-I diagnosis. Characteristics were balanced between cohorts using inverse probability of treatment weighting (IPTW). Outcomes evaluated post-index included all-cause and mental health (MH)–related HRU (hospitalizations, emergency department [ED] visits, outpatient visits), total healthcare costs (medical + pharmacy), and treatment patterns. HRU and healthcare costs were reported per patient-year (PPY) and compared between cohorts using rate ratios and 95% CIs estimated using nonparametric bootstrap procedures. Treatment patterns were analyzed descriptively, with standardized differences ≥10% considered important. Results: After IPTW, cohorts included 1,409 patients who initiated cariprazine first and 1,621 patients who initiated cariprazine subsequently; the average (standard deviation, SD) observation period was 678 (373) and 758 (389) days for first and subsequent initiators, respectively. Patients who initiated cariprazine first had 23% fewer all-cause hospitalizations and 28% fewer MH-related hospitalizations PPY (each comparison, p < 0.001). Rates of all-cause and MH-related outpatient visits were significantly lower in patients who initiated cariprazine first versus subsequently (each comparison, p < 0.001), while rates of ED visits were similar. Relative to subsequent initiators, first initiators incurred $2,587 and $2,130 lower all-cause and MH-related total healthcare costs PPY, respectively (each comparison, p < 0.05). Before starting cariprazine, first initiators used fewer BP-I–related medications on average than subsequent initiators (2.6 vs 3.9; standardized difference = 23.9%). Limitations: Potential coding inaccuracies and residual confounding. Conclusions: In this real-world database analysis, patients with BP-I who initiated cariprazine as their first AA had lower rates of HRU and incurred lower costs than patients who initiated cariprazine as a subsequent AA. © 2024 AbbVie. Published by Informa UK Limited, trading as Taylor & Francis Group.

Overview

CoChat Summary

TL;DR

In a retrospective US claims analysis, adults with bipolar I disorder (BP-I) who started cariprazine as their first atypical antipsychotic (AA) had lower healthcare resource utilization and costs than those who started cariprazine after another AA. The authors conclude that earlier cariprazine initiation may be associated with fewer hospitalizations and outpatient visits and lower total healthcare costs.

Key findings

  • First initiators had 23% fewer all-cause hospitalizations and 28% fewer mental health (MH)-related hospitalizations per patient-year (PPY) than subsequent initiators (0.27 vs 0.35 PPY and 0.22 vs 0.31 PPY; each p < 0.001).
  • First initiators had 12% fewer all-cause outpatient visits and 21% fewer MH-related outpatient visits (31.33 vs 35.58 PPY and 19.80 vs 25.09 PPY; each p < 0.001); ED visit rates were similar.
  • Total all-cause healthcare costs were $2,587 lower PPY for first initiators ($18,318 vs $20,906; p < 0.05), and total MH-related healthcare costs were $2,130 lower PPY ($11,480 vs $13,611; p < 0.05).
  • Before cariprazine, first initiators used fewer BP-I–related medications on average than subsequent initiators (2.6 vs 3.9; standardized difference = 23.9%).

Methods

  • Retrospective claims-based analysis using Merative MarketScan Commercial, Medicare Supplemental, and Multi-State Medicaid databases; adults aged ≥18 years with a first BP-I diagnosis claim on or after January 1, 2016, and ≥1 outpatient cariprazine dispensing after index.
  • Cohorts were patients who initiated cariprazine as their first AA after BP-I diagnosis (n = 1,409) versus those who initiated cariprazine after at least one other AA (n = 1,621); baseline characteristics were balanced using inverse probability of treatment weighting (IPTW).
  • Outcomes included all-cause and MH-related hospitalizations, ED visits, outpatient visits, total healthcare costs (medical + pharmacy), and treatment patterns; HRU and costs were reported PPY and compared using rate ratios and 95% CIs from nonparametric bootstrap procedures.

Limitations

  • Stated: potential coding inaccuracies and residual confounding; unmeasured confounding, including treatment resistance and unavailable socioeconomic variables; possible survivor bias; PPY comparisons cannot capture timing of HRU/costs; US-only data limit generalizability; part of the analysis occurred during the COVID-19 pandemic.
  • Evident from the text: this is an observational claims analysis, so associations are not causal; cohorts differed in prior AA use and time from diagnosis to cariprazine initiation, and follow-up duration differed between groups.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/13696998.2024.2419721

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 21 Not checked · 75 Own results and interpretations

45 more claims

Create a free account to see all 96 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 27

Create a free account to see these claims.

Citations

Cites

Show all 31 references

Cited by

See all 3

Metadata

Authors
Cutler, A. J., Laliberté, F., Germain, G., MacKnight, S. D., Boudreau, J., Wade, S. W., & Parikh, M.
Affiliations
  • SUNY Upstate Medical University (US)
  • Groupe d’analyse
  • Wade Outcomes Research and Consulting
  • AbbVie (United States) (US)
Corresponding author
Parikh, Mousam
Venue
Journal of Medical Economics
Published
2024-11-12
Volume
27
Issue
1
Pages
1472-1484
ISSN
  • 1369-6998 (ISSN-L)
  • 1941-837X
OpenAlex
W4404297940
Cited by
3
References
31
Citations by year
2026: 1 · 2025: 2
FWCI
0.71
Type
journal article
Language
en
Open access
Locations
  • Journal of Medical Economics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Figshare (cc-by)
Funders
AbbVie
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
cariprazine, bipolar I disorder, atypical antipsychotics, healthcare resource utilization, health care costs, hospitalization, emergency department visits, outpatient visits, polypharmacy, treatment patterns, real-world evidence, Medicare Supplemental, Medicaid, private insurance, inverse probability of treatment weighting, MarketScan
MeSH terms
Adolescent, Adult, Bipolar Disorder, Emergency Service, Hospital, Health Expenditures, Female, Health Resources, Health Services, Hospitalization, Humans, Insurance Claim Review, Male, Middle Aged, Patient Acceptance of Health Care, Piperazines, Retrospective Studies, Antipsychotic Agents, United States, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-26, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-26 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder. https://app.cochat.ai/papers/10.1080/13696998.2024.2419721
The paper
Cutler, A. J., Laliberté, F., Germain, G., MacKnight, S. D., Boudreau, J., Wade, S. W., & Parikh, M. (2024). Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder. Journal of Medical Economics. https://doi.org/10.1080/13696998.2024.2419721

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.